|
Indications:
Rheumatoid arthritis:
Remsima, in combination with methotrexate, is indicated for:
The reduction of signs and symptoms as well as the improvement in physical function in
-patients with active disease when the response to disease-modifying drugs, including methotrexate, has been inadequate.
-patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by x-ray, has been demonstrated (see section 5.1).
Ankylosing spondylitis
Remsimais indicated for:
Treatment of ankylosingspondylitis, in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy.
Psoriatic arthritis
Remsima, in combination with methotrexate, is indicated for:
Treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to disease-modifying anti-rheumatoid drugs.
Psoriasis
Remsimais indicated for:
Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultraviolet A (PUVA)(see section 5.1).
|